We would love to hear your thoughts about our site and services, please take our survey here.
Firsttothemoon - While I agree I’d like both the multi bags and in a tax wrapper..
What’s changed!!! The method of investment for one, no nice tax safe wrapper in ISA or SIPP if delisted, that’s big for PIs. I’d add the spread is also far more painful now and will get worse. Don’t get me wrong risk = reward, and I’m sure there is ££ in here for those willing to take the risk.
Odey selling but in such small % amounts.
Agree FFS, a buy out would with decent price be a home run if delisted, of course could also be resisted through sump once in profit.
I chickened out and sold, probably be licking my wounds later but rather that then lose money.
Wanted to learn, but found little information or support from my broker re delisting so am out. Good looks to all holders.
I hate investing in something I don’t fully understand, but then this could be a worthwhile lesson given circumstances and risk vs reward is attractive. So I am in and have primarily based my investing on NAV. I think the 17p is realistic and even 1/2 of this would be a good result at these lows. So whatever happens tomorrow with the vote will hopefully lead to profit. Has anyone on here been though a similar delisting before? This would be my 1st and all the web searching doesn’t answer much so I’m also invested here to learn, If the vote goes as expected I guess holders will simply be holders of an unlisted / unregulated company? Any thoughts or insights would be much appreciated.
`Rought notes for your consideration....
UK Population 62M Vaccine effective for 55.8M leaves 6.2M so balance of 1.2M still likely need treatment Gilead’s gov price $2340 private $2600 with 80/20 split would be near $3.0B or £2.3B divided between treatments offered, I’m happy to hold or even buy more at this price....
Let’s be real here, this is a company that has grown tremendously fast, has a market cap of 196m, a nav of 1.35 and a wonderful pipeline regardless of C19. It had profit in 2017 and will likely see another breakthrough in the next 24 months. I’m in at 1.80 but averaged up with the offer, this is long for me, I’ll keep one eye on it for 2-3 years, and hope to see it still fledging.
Me too, managed to top up at 12p - not the best of news but I think over sold with nerves on delays. I originally bought at 12p sold are 21p, got in again at 18p and now averaged down. Long term hoping this will come good, especially with Oil generally in recovery but truth be told I’m no truly long in UJO.
Kford - probably relatives in that co too
Omne - I respect your opinion but I have an opposing view, I believe BRH are an investment and incubator company, as such they grow business to a point and get out. Not all businesses invested in will succeed, and some may take a long time. I really sense they made sound financial decisions to cash in and now they are in a position to back other investments, rinse and repeat. Who knows if RMS P2F will gain market caps that’ll overtake BRH, but I somehow doubt it.
So a director sold when the SP jumped x5, what’s the betting insiders will buy back in at lower levels? Any Licensing deals, sit back watch cash roll in.
Enjoy the laugh Ramboo, speak as a former customer, not as a shareholder.
But seeing little up in the past 6 month I sold up too.
This is up on costs saved due to Covid, but otherwise an awful company, poor service, poor communication, may they enjoy the temporary shine, but I believe people will leave in droves once pandemic has eased.
Way I see it Capacity can more easily be increased with resources and automation if given budget. Test is proven and protected, that was harder to deliver.
That briefing should reflect hugely positive for us tomorrow. Good luck all
Actually Troll I sold my stake today, not that I have issue with UKOG, as just saw a better opportunity elsewhere for now, BUT it wasn’t easy I had to try for quote many times and the reduce my sells to smaller chunks. That said I wish holders well and I do expect to reinvest here somewhen